← 產業報告目錄
Blood Brain Barrier Market Share & Trends Analysis Report, Distribution by Type of Molecule (Biologics and Small Molecules), , Target Disease Indication (Amyotrophic Lateral Sclerosis, Leptomeningeal Carcinomatosis, Mucopolysaccharidosis Type II (Hunter Syndrome), Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A) and Multiple Sclerosis) and Therapeutic Area (Lysosomal Storage Disorders, Neurodegenerative Disorders and Neuro-Oncology Disorders), By Route of Administration, By Region, and Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-28頁數 180報告編號 INSIGHTACE-59c80c25e2
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Blood Brain Barrier Market stood at USD 35.2 Mn in 2023, and is forecasted to reach USD 514.8 Mn by 2031, recording a CAGR of 40.9% from 2024 through 2031.
The Blood Brain Barrier sector involves The Blood-Brain Barrier (BBB) represents a selective, semipermeable membrane that separates circulating blood from the brain and extracellular fluid in the central nervous system (CNS). This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is bolstered by growing appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Blood Brain Barrier Market Snapshot
Chapter 4. Global Blood Brain Barrier Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: Distribution by Type of Molecule Estimates & Trend Analysis
5.1. Distribution by Type of Molecule & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution by Type of Molecule:
5.2.1. Biologics
5.2.2. Small Molecules
Chapter 6. Market Segmentation 2: Route of Administration Estimates & Trend Analysis
6.1. Route of Administration & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:
6.2.1. Intravenous
6.2.2. Oral
Chapter 7. Market Segmentation 3: Target Disease Indication Estimates & Trend Analysis
7.1. Target Disease Indication & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Target Disease Indication:
7.2.1. Amyotrophic Lateral Sclerosis,
7.2.2. Leptomeningeal Carcinomatosis,
7.2.3. Mucopolysaccharidosis Type II (Hunter Syndrome)
7.2.4. Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A)
7.2.5. Multiple Sclerosis
Chapter 8. Market Segmentation 4: Therapeutic Area Estimates & Trend Analysis
8.1. Route of Administration & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Therapeutic Area:
8.2.1. Lysosomal Storage Disorders
8.2.2. Neurodegenerative Disorders
8.2.3. Neuro-Oncology Disorders
Chapter 9. Blood Brain Barrier Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Distribution by Type of Molecule, 2023-2031
9.1.2. North America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2023-2031
9.1.3. North America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Target Disease Indication, 2023-2031
9.1.4. North America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Therapeutic Area, 2023-2031
9.1.5. North America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
9.2. Europe
9.2.1. Europe Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Distribution by Type of Molecule, 2023-2031
9.2.2. Europe Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2023-2031
9.2.3. Europe Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Target Disease Indication, 2023-2031
9.2.4. Europe Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Therapeutic Area, 2023-2031
9.2.5. Europe Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Distribution by Type of Molecule, 2023-2031
9.3.2. Asia Pacific Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2023-2031
9.3.3. Asia-Pacific Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Therapeutic Area, 2023-2031
9.3.4. Asia-Pacific Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Therapeutic Area, 2023-2031
9.3.5. Asia Pacific Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
9.4. Latin America
9.4.1. Latin America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Distribution by Type of Molecule, 2023-2031
9.4.2. Latin America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2023-2031
9.4.3. Latin America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Target Disease Indication, 2023-2031
9.4.4. Latin America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Therapeutic Area, 2023-2031
9.4.5. Latin America Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Distribution by Type of Molecule, 2023-2031
9.5.2. Middle East & Africa Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Route of Administration, 2023-2031
9.5.3. Middle East & Africa Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Target Disease Indication, 2023-2031
9.5.4. Middle East & Africa Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts Therapeutic Area, 2023-2031
9.5.5. Middle East & Africa Blood Brain Barrier Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. 2-BBB Medicines
10.2.2. AbbVie
10.2.3. AC Immune
10.2.4. Acorda Therapeutics
10.2.5. Adamas Pharmaceuticals
10.2.6. Amgen
10.2.7. Alector
10.2.8. Attralus
10.2.9. Alnylam Pharmaceuticals
10.2.10. Angiochem
10.2.11. Biogen
10.2.12. Biohaven
10.2.13. Denali Therapeutics
10.2.14. Eli Lilly
10.2.15. Genentech
10.2.16. Ionis Pharmaceuticals
10.2.17. Johnson & Johnson
10.2.18. Lundbeck
10.2.19. Merck
10.2.20. Neurocrine Biosciences
10.2.21. Novartis
10.2.22. Pfizer
10.2.23. Roche
10.2.24. Sanofi
10.2.25. Takeda Pharmaceuticals
10.2.26. Teva Pharmaceutical
10.2.27. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們